Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Next Gen Multiplexing Firm Genalyte Raises $12M Series B Financing

Published: Thursday, September 27, 2012
Last Updated: Thursday, September 27, 2012
Bookmark and Share
Maverick platform is much simpler, faster and more sensitive, flexible and cost-effective than current options.

Genalyte, Inc. has announced completion of an $11.8 million Series B financing.

New investors Redmile Group and Claremont Creek Ventures and private investors from Genalyte’s Series A round participated in the Series B financing.

Genalyte intends to use the new funds primarily for commercialization of its Maverick™ platform and its highly multiplexed panels for autoimmune and immunoassay applications.

Genalyte has pioneered an entirely new approach to immunodetection using silicon chip manufacturing methods.

The Maverick platform uses a technology called silicon photonics to directly measure protein binding between antibodies and antigens or hybridization of nucleic acids.

This technology eliminates the need for complex processing associated with current multiplexed testing, while leveraging the manufacturing advantages of silicon chips.

Genalyte is preparing to launch the Maverick platform this summer, initially addressing the autoimmunity research and testing markets.

“By applying advances in silicon photonics to the life sciences, we have been able to develop a completely new approach to biological detection that provides major advantages to researchers and, eventually, to clinicians,” commented Genalyte CEO and founder Cary Gunn.

Gunn continued, “Our initial funding enabled us to fully develop and refine the silicon photonics biosensor consumables that are the heart of the Maverick system, along with the instrument itself and our initial multiplexed immunology panels. This new financing provides us with the resources to launch the platform in the coming months and to begin to populate it with a wide variety of proprietary assays for multiple applications.”

The Maverick platform runs scalable multiplexed assays using a silicon chip that contains arrays of photonic microring sensors that can simultaneously analyze multiple proteins from a single small sample.

Assays do not require the washes, incubations, reagents or other processing steps typically associated with sample preparation.

The assays are therefore simple to use and rapid-results are available in only 15 minutes, including just two minutes of hands-on time. The Maverick platform has a large dynamic range and excellent sensitivity, with good reproducibility and no cross talk.

Dr. Gunn continued, “By using silicon-based technologies, we can provide customers with unprecedented system performance while leveraging the highly efficient production characteristic of traditional silicon chip manufacturing. During our four years of development, we and our academic collaborators generated a large number of peer-reviewed studies that provide important validation for the superiority of our detection data and the breadth of applications that are possible. We look forward to unveiling the Maverick platform at upcoming scientific meetings and to making this exciting new technology available to researchers worldwide.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genalyte Signs on European Distributors as Maverick System Gains CE Mark
Mokascience, Bucher Biotec and KRD Molecular Technologies will distribute Maverick system and Genalyte multiplex assays in selected European territories.
Thursday, July 25, 2013
Genalyte Wins $500K for Early Detection of Type 1 Diabetes
Unique multiplexing capabilities of Maverick™ detection system could enable early detection of Type 1 diabetes and allow for potentially curative interventions.
Thursday, December 13, 2012
Scientific News
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Four Gut Bacteria Decrease Asthma Risk in Infants
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos